Medical management of gastric cancer: A 2014 update

doi:10.3748/wjg.v20.i38.13637

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 38

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6991)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

556

WORD

198

HTML

3730

Tables (1-2)

213

Sum=4697

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1268

Download

1026

Sum=2294

Oct 14, 2014 (publication date) through Jul 17, 2024

Times Cited of This Article

Times Cited (29)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 14, 2014; 20(38): 13637-13647
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13637

Table 2 Major phase III trials for gastric cancer in the advanced setting

Trial	n	Treatment arms	HR for overall survival (P value)	Survival comparison
Advanced gastric cancer - first-line
Bang et al[39]	584	CX, CF and trastuzumab vs CX and CF¹	0.74 (0.0046)	Overall survival: 13.8 mo vs 11.1 mo
Ohtsu et al[42]	774	Cisplatin and 5-FU vs cisplatin, 5-FU and bevacizumab	0.87 (0.1002)	Overall survival: 10.1 mo vs 12.1 mo
Ohtsu et al[42]	774	Cisplatin and 5-FU vs cisplatin, 5-FU and bevacizumab	0.87 (0.1002)	PFS: 5.3 mo vs 6.7 mo
Lordick et al[44]	904	CX vs CX and cetuximab	1.004 (0.9547)	Overall survival: 10.7 mo vs 9.4 mo
Waddell et al[45]	553	EOC vs mEOC–P	1.37 (0.013)	Overall survival: 11.3 mo vs 8.8 mo
Van Cutsem et al[37]	445	DCF vs CF	TTP 1.47 (< 0.001) OS 1.29 (0.02)	Time to progression: 5.6 mo vs 3.7 mo, 9.2 mo vs 8.6 mo
Koizumi et al[40]	305	S-1 and cisplatin vs S-1	0.77 (0.04)	Overall survival: 13.0 mo vs 11.0 mo
Ajani et al[66]	1053	Cisplatin and S-1 vs cisplatin and 5-FU	0.92 (0.20)	Overall survival: 8.6 mo vs 7.9 mo
Hecht et al[67]	545	CapeOx and lapatinib vs CapeOx and placebo	0.91 (0.35)	Overall survival: 12.2 mo vs 10.5 mo
Advanced gastric cancer - second-line
Ohtsu et al[51]	656	BSC and placebo vs BSC and everolimus	0.90 (0.1244)	Overall survival: 4.3 mo vs 5.4 mo
Fuchs et al[47]	355	BSC and ramucirumab vs BSC	0.776 (0.047)	Overall survival: 5.2 mo vs 3.8 mo
Bang et al[52]	261	Lapatinib and paclitaxel vs paclitaxel	0.84 (0.2088)	Overall survival: 11.0 mo vs 8.9 mo
Kang et al[50]	202	BSC vs docetaxel or irinotecan	0.657 (0.007)	Overall survival: 3.8 mo vs 5.3 mo
Thuss-Patience et al[48]	40	Irinotecan and BSC vs BSC	0.48 (0.012)	Overall survival: 4.0 mo vs 2.4 mo
Cook et al[49]	168	Docetaxel and ASC vs ASC	0.67 (0.01)	Overall survival: 5.2 mo vs 3.6 mo

¹Hazard ratio reduced to 0.8 on follow-up analysis. 5-FU: 5-Fluorouracil; ASC: Active symptom control; BSC: Best supportive care; CapeOx: Capecitabine and oxaliplatin; CF: Cisplatin and 5-FU; CX: Cisplatin and capecitabine; DFS: Diseas-free survival; ECF: Epirubicin, cisplatin and 5-FU; ECX: Epirubicin, cisplatin and capecitabine; EOC: Epirubicin, oxaliplatin and capecitabine; HR: Hazard ratio; mEOC–P: EOC plus panitumumab; PFS: Progression-free survival; RFS: Relapse-free survival; UFT: Tegafur and uracil; XELOX: Capecitabine and oxaliplatin; XP: Capecitabine and cisplatin; XRT: XP and radiotherapy.

Citation: Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 2014; 20(38): 13637-13647
URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13637.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13637